The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Drugs for Malaria Market Research Report 2024
Synopsis
Drugs for malaria or antimalarial medications are also known as anti-malarial drugs. Anti-malarial drugs treat or Prevention malaria, a disease that occurs in tropical, subtropical, and some temperate regions of the world. The disease is caused by a parasite, Plasmodium, which belongs to a group of one-celled organisms known as protozoa. The only way to get malaria is to be bitten by a certain type of mosquito that has bitten someone who has the disease.
Anti-malarial Drugs are available only with a physician's prescription. They come in tablet, capsule, and injectable forms. Among the commonly used anti-malarial drugs are chloroquine, mefloquine, primaquine, pyrimethamine, and quinine.
The global Drugs for Malaria market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
In the U.S. market, the major manufacturers are Cipla, Guilin Southern Medicine, IPCA Laboratories, GlaxoSmithKline, Mylan Labs, Roche, Novartis, Sanofi Aentis and Ajanta Pharma, etc, with about 73% market shares.
This report aims to provide a comprehensive presentation of the global market for Drugs for Malaria, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Malaria.
Report Scope
The Drugs for Malaria market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs for Malaria market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Malaria companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Cipla
Guilin Pharmaceutical
IPCA Laboratories
GlaxoSmithKline
Mylan Labs
Roche
Novartis
Sanofi Aventis
Ajanta Pharma
Segment by Type
Aryl Aminoalcohol Compounds
Antifolate Compounds
Artemisinin Compounds
Segment by Application
Prevention
Treatment
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs for Malaria companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Drugs for malaria or antimalarial medications are also known as anti-malarial drugs. Anti-malarial drugs treat or Prevention malaria, a disease that occurs in tropical, subtropical, and some temperate regions of the world. The disease is caused by a parasite, Plasmodium, which belongs to a group of one-celled organisms known as protozoa. The only way to get malaria is to be bitten by a certain type of mosquito that has bitten someone who has the disease.
Anti-malarial Drugs are available only with a physician's prescription. They come in tablet, capsule, and injectable forms. Among the commonly used anti-malarial drugs are chloroquine, mefloquine, primaquine, pyrimethamine, and quinine.
The global Drugs for Malaria market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
In the U.S. market, the major manufacturers are Cipla, Guilin Southern Medicine, IPCA Laboratories, GlaxoSmithKline, Mylan Labs, Roche, Novartis, Sanofi Aentis and Ajanta Pharma, etc, with about 73% market shares.
This report aims to provide a comprehensive presentation of the global market for Drugs for Malaria, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Malaria.
Report Scope
The Drugs for Malaria market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs for Malaria market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Malaria companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Cipla
Guilin Pharmaceutical
IPCA Laboratories
GlaxoSmithKline
Mylan Labs
Roche
Novartis
Sanofi Aventis
Ajanta Pharma
Segment by Type
Aryl Aminoalcohol Compounds
Antifolate Compounds
Artemisinin Compounds
Segment by Application
Prevention
Treatment
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs for Malaria companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Malaria Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Aryl Aminoalcohol Compounds
1.2.3 Antifolate Compounds
1.2.4 Artemisinin Compounds
1.3 Market by Application
1.3.1 Global Drugs for Malaria Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Prevention
1.3.3 Treatment
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drugs for Malaria Market Perspective (2019-2030)
2.2 Drugs for Malaria Growth Trends by Region
2.2.1 Global Drugs for Malaria Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Drugs for Malaria Historic Market Size by Region (2019-2024)
2.2.3 Drugs for Malaria Forecasted Market Size by Region (2025-2030)
2.3 Drugs for Malaria Market Dynamics
2.3.1 Drugs for Malaria Industry Trends
2.3.2 Drugs for Malaria Market Drivers
2.3.3 Drugs for Malaria Market Challenges
2.3.4 Drugs for Malaria Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs for Malaria Players by Revenue
3.1.1 Global Top Drugs for Malaria Players by Revenue (2019-2024)
3.1.2 Global Drugs for Malaria Revenue Market Share by Players (2019-2024)
3.2 Global Drugs for Malaria Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drugs for Malaria Revenue
3.4 Global Drugs for Malaria Market Concentration Ratio
3.4.1 Global Drugs for Malaria Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Malaria Revenue in 2023
3.5 Drugs for Malaria Key Players Head office and Area Served
3.6 Key Players Drugs for Malaria Product Solution and Service
3.7 Date of Enter into Drugs for Malaria Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Malaria Breakdown Data by Type
4.1 Global Drugs for Malaria Historic Market Size by Type (2019-2024)
4.2 Global Drugs for Malaria Forecasted Market Size by Type (2025-2030)
5 Drugs for Malaria Breakdown Data by Application
5.1 Global Drugs for Malaria Historic Market Size by Application (2019-2024)
5.2 Global Drugs for Malaria Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Drugs for Malaria Market Size (2019-2030)
6.2 North America Drugs for Malaria Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Drugs for Malaria Market Size by Country (2019-2024)
6.4 North America Drugs for Malaria Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drugs for Malaria Market Size (2019-2030)
7.2 Europe Drugs for Malaria Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Drugs for Malaria Market Size by Country (2019-2024)
7.4 Europe Drugs for Malaria Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Malaria Market Size (2019-2030)
8.2 Asia-Pacific Drugs for Malaria Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Drugs for Malaria Market Size by Region (2019-2024)
8.4 Asia-Pacific Drugs for Malaria Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drugs for Malaria Market Size (2019-2030)
9.2 Latin America Drugs for Malaria Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Drugs for Malaria Market Size by Country (2019-2024)
9.4 Latin America Drugs for Malaria Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Malaria Market Size (2019-2030)
10.2 Middle East & Africa Drugs for Malaria Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Drugs for Malaria Market Size by Country (2019-2024)
10.4 Middle East & Africa Drugs for Malaria Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Cipla
11.1.1 Cipla Company Detail
11.1.2 Cipla Business Overview
11.1.3 Cipla Drugs for Malaria Introduction
11.1.4 Cipla Revenue in Drugs for Malaria Business (2019-2024)
11.1.5 Cipla Recent Development
11.2 Guilin Pharmaceutical
11.2.1 Guilin Pharmaceutical Company Detail
11.2.2 Guilin Pharmaceutical Business Overview
11.2.3 Guilin Pharmaceutical Drugs for Malaria Introduction
11.2.4 Guilin Pharmaceutical Revenue in Drugs for Malaria Business (2019-2024)
11.2.5 Guilin Pharmaceutical Recent Development
11.3 IPCA Laboratories
11.3.1 IPCA Laboratories Company Detail
11.3.2 IPCA Laboratories Business Overview
11.3.3 IPCA Laboratories Drugs for Malaria Introduction
11.3.4 IPCA Laboratories Revenue in Drugs for Malaria Business (2019-2024)
11.3.5 IPCA Laboratories Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Detail
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Drugs for Malaria Introduction
11.4.4 GlaxoSmithKline Revenue in Drugs for Malaria Business (2019-2024)
11.4.5 GlaxoSmithKline Recent Development
11.5 Mylan Labs
11.5.1 Mylan Labs Company Detail
11.5.2 Mylan Labs Business Overview
11.5.3 Mylan Labs Drugs for Malaria Introduction
11.5.4 Mylan Labs Revenue in Drugs for Malaria Business (2019-2024)
11.5.5 Mylan Labs Recent Development
11.6 Roche
11.6.1 Roche Company Detail
11.6.2 Roche Business Overview
11.6.3 Roche Drugs for Malaria Introduction
11.6.4 Roche Revenue in Drugs for Malaria Business (2019-2024)
11.6.5 Roche Recent Development
11.7 Novartis
11.7.1 Novartis Company Detail
11.7.2 Novartis Business Overview
11.7.3 Novartis Drugs for Malaria Introduction
11.7.4 Novartis Revenue in Drugs for Malaria Business (2019-2024)
11.7.5 Novartis Recent Development
11.8 Sanofi Aventis
11.8.1 Sanofi Aventis Company Detail
11.8.2 Sanofi Aventis Business Overview
11.8.3 Sanofi Aventis Drugs for Malaria Introduction
11.8.4 Sanofi Aventis Revenue in Drugs for Malaria Business (2019-2024)
11.8.5 Sanofi Aventis Recent Development
11.9 Ajanta Pharma
11.9.1 Ajanta Pharma Company Detail
11.9.2 Ajanta Pharma Business Overview
11.9.3 Ajanta Pharma Drugs for Malaria Introduction
11.9.4 Ajanta Pharma Revenue in Drugs for Malaria Business (2019-2024)
11.9.5 Ajanta Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
